NCT03776812: A trial that was reported late by Corcept Therapeutics
This trial has reported, although it was 164 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT03776812 |
|---|---|
| Title | A Phase 2, Randomized, Open-Label, 3-arm Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Jan. 28, 2019 |
| Completion date | March 31, 2023 |
| Required reporting date | March 30, 2024, midnight |
| Actual reporting date | Sept. 11, 2024 |
| Date last checked at ClinicalTrials.gov | March 28, 2025 |
| Days late | 164 |